University of California spinout Addition Therapeutics emerged from stealth with roughly $100M in financing to commercialize a platform it says enables improved genetic medicine delivery. The company disclosed proprietary PRINT technology and appointed experienced biotech executives to its team, positioning the firm to accelerate programs in chronic and rare diseases. Founders and investors emphasized the platform’s potential to address delivery bottlenecks that limit gene therapy efficacy and manufacturability. Addition’s public messaging highlights product candidates and a development roadmap that aims to move lead programs into IND‑enabling studies; the firm will use the Serie(s) A funding to scale operations and pursue regulatory milestones.